It is worth speculating which sector will survive the bear. I have speculated in the past that it would be niche biotechs. Solar, China, Oil could continue, but it is ususally some different sector that leads the way. I am surprised by how many we have covered on Wallstrip. Today, it’s Gilead’s turn for Julie .

Here is Gilead’s Google Finance Page .

I have said before that too many eyes are on the old biotech leaders Amgen and Genentech . Today’s biotech group is led by distributors and niche drugs – like Auxilium (one of Wallstrip’s best performers – I am long – and today’s Gilead).

I am passing on new positions right now, but the stock is in an amazing uptrend. Brian takes a look at possible entry points:

What do you think?